Page
To prevent a COVID-19 infection, the CDC advises improving ventilation in your home.
Good ventilation means filtering the air inside your house, getting fresh air in, and improving air…
Page
CDC Updated Recommendations for Moderately or Severely Immunocompromised Individuals
On October 19, the U.S. Centers for Disease Control and Prevention (CDC) updated its…
Videos
IMF Patient and Family Webinar
IMF Chairman of the Board and Chief Scientific Officer Dr. Brian G.M. Durie moderates presentations with the following myeloma experts:
Paul Richardson, MD (Dana-Farber Cancer Institute, Boston, MA)
Saad Usmani, MD…
News Article
Read the Healthline Article: How to Talk with Others About Your Multiple Myeloma Diagnosis
In this Healthline article published August 17, 2022, IMF Patient, President, and CEO Yelak Biru says; “If you don’t have that conversation, there’s going to be a mismatch in my ability to receive…
Videos
Bispecific Monoclonal Antibodies and Multiple Myeloma
In this week's "Ask Dr. Durie" myeloma expert Dr. Brian G.M. Durie discusses what patients should know about bispecific antibodies.
The BOTTOM LINE: Bispecific antibodies are new upcoming therapies for myeloma…
News Article
On Thursday, August 11, the Center for Disease Control and Prevention (CDC) streamlined its COVID-19 guidance for the public to better…
Videos
What Do Care Providers Need To Know About CAR T-Cell Therapy?
Multiple myeloma expert Dr. Brian G.M. Durie discusses what care providers should know about CAR T-cell therapy.
The BOTTOM LINE: Patients and their care providers should discuss carefully with their medical team…
News Article
On Wednesday, August 10, Bristol Myers Squibb and 2seventy bio, Inc. announced the positive topline results from KarMMa-3—a Phase 3, global, randomized, multicenter, open-label study evaluating ABECMA® (idecabtagene vicleucel) compared to standard combination regimens in adults…
Page
Multiple Myeloma and Plasma Cell Disorders: Update On Diagnosis, Prognosis, Treatment, and Supportive Care
This supplement to JADPRO has been developed by members of the International Myeloma Foundation (IMF) Nurse Leadership Board.
Videos
Virtual Multiple Myeloma Community Workshop A virtual multiple myeloma workshop addressing the needs specific to communities in the East South Central Region of the United States.The IMF Virtual Regional Community Workshop will include an introduction to myeloma, upfront treatments at…
News Article
On Friday, July 29, Laughs 4 Life returned to Hattiesburg, MS. This year’s successful event featured comedian Leanne Morgan and special guests, James Austin Johnson and Keith Alberstadt and was held at the Hattiesburg Saenger Theater—with over 1,000 attendees!
The International Myeloma…
Audio
In Memoriam
During his life, Nick Lenoir made every attempt to share his story of his multiple myeloma journey to give hope to others in the community. In this podcast, Nick says about the disease, "How you approach it and how you cope with it is going to be different, as well as how the myeloma…
News Article
By Robin Levy IMF Senior Director, Public Policy & AdvocacyThere are many new ideas in the cancer public policy space, with two proposals to help cancer patients being discussed most frequently: President Biden’s Cancer Moonshot initiative and the creation of a new agency known as ARPA-H…
News Article
Support the International Myeloma Foundation's Mission through Your Legacy
By Lynn K. Green, Ed.D.
IMF Senior Vice President, Philanthropy
The mission of the International Myeloma Foundation (IMF) is to improve the quality of life of myeloma patients while working toward prevention…
Author
Serdar Erdoğan
Director, Global Myeloma Action Network and European & Middle Eastern Patient Programs
Serdar joined the IMF in September 2018 with seven years of experience in the non-profit sector, specializing in corporate communications and development. For the prior four…
Videos
Virtual Multiple Myeloma Community Workshop A virtual multiple myeloma workshop addressing the needs specific to communities in the Pacific Southwest Region of the United States.The IMF Virtual Regional Community Workshop will include an introduction to myeloma, upfront treatments at diagnosis…
Videos
Early versus delayed ASCT in newly diagnosed myeloma patients
Myeloma expert Dr. Brian G.M. Durie discusses the results from the DETERMINATION trial presented at the 2022 ASCO and EHA meetings and the role of early versus delayed autologous stem cell transplant (ASCT) in newly diagnosed myeloma…
News Article
Videos
Virtual Multiple Myeloma Community Workshop A virtual multiple myeloma workshop addressing the needs specific to communities in the South Atlantic Region of the United States.The IMF Virtual Regional Community Workshop will include an introduction to myeloma, upfront treatments at diagnosis,…
Videos
Clinical trials evaluating CAR T-cell treatment in newly diagnosed myeloma
Myeloma expert Dr. Brian G.M. Durie discusses if CAR T-cell therapy will be used in newly diagnosed multiple myeloma and which clinical trials are evaluating the benefits of early CAR T treatment.
The…
Page
The following videos, presented by Medscape Oncology, are designed for healthcare practitioners to earn continuing education (CE) credits.
In this CE program, nurses from the IMF's Nurse Leadership Board (NLB) present new drugs, regimens, and strategies for multiple myeloma.
Videos
Should myeloma patients undergo mass spectrometry testing?
Myeloma expert Dr. Brian G.M. Durie discusses if mass spectrometry is ready for commercial use.
The BOTTOM LINE: With a better understanding and commercial availability, mass spectrometry will be a powerful…
Page
Presented by Medscape Oncology, this activity is designed for continuing medical education (CME) credits. Moderated by Dr. Brian G.M. Durie (Chief Scientific Officer and Chairman of the Board of the International Myeloma Foundation), this activity features myeloma expert Dr.…
Videos
Updates on Phase 1b/2 of CARTITUDE-1 (Cilta-Cel) Study Presented at ASCO 2022
Dr. Saad Usmani Discusses Updated Results (2 years post-LPI) in Phase 1b/2 (CARTITUDE-1) Study of Cilta-Cel in RRMM patients
Abstract Title:
Phase 1b/2 study of ciltacabtagene autoleucel, a BCMA-directed…
Videos
Phase 2 IFM 2018-04 Study Results Presented at ASCO 2022
Dr. Cyrille Touzeau Discusses Results of the Phase 2 IFM 2018-04 Study in High-Risk, Transplant-Eligible NDMM Patients
Abstract title:
Daratumumab carfilzomib lenalidomide and dexamethasone as induction therapy in high-…
Videos
DREAMM-5 Study: BLENREP Combined with Nirogacestat Presented at ASCO 2022
Dr. Sagar Lonial Discusses DREAMM-5 Study of BLENREP (belantamab mafodotin) Combined with Nirogacestat in RRMM patients
Abstract Title:
Synergistic effects of low-dose belantamab mafodotin in combination with a gamma…
Videos
Evaluation of Teclistamab in RRMM Patients Following Exposure to Other BCMA-Targeted Agents Presented at EHA 2022
Dr. Cyrille Touzeau Discusses Evaluation of Teclistamab in RRMM Patients Following Exposure to Other BCMA-Targeted Agents
Abstract Title:
Evaluating Teclistamab in Patients…
Videos
Response Rates Among t(11; 14) MM Patients Receiving Triplet Induction Therapy Presented at ASCO 2022
Dr. Nisha Joseph Discusses Response Rates Among t(11; 14) MM Patients Receiving Triplet Induction Therapy
Abstract Title:
Prognostic impact of t(11;14) on PFS1 among patients with myeloma…
Videos
Post Hoc Analysis of the GRIFFIN Trial Presented at ASCO 2022
Dr. Cesar Rodriguez Presents Post Hoc Analysis of Sustained MRD Negativity (GRIFFIN Trial) in TE NDMM Patients
Abstract Title:
Daratumumab (DARA) + lenalidomide, bortezomib, and dexamethasone (RVd) in transplant-eligible…
Videos
Dr. Niels W.C.J. van de Donk (VU University Medical Center—Amsterdam, Netherlands) compares the efficacy of Teclistimab versus current treatments in patients with triple-class exposed relapsed/refractory multiple myeloma
Abstract Title:
Comparative Efficacy of Teclistamab Versus Current…
Videos
This M-Power Charlotte virtual myeloma workshop includes:
Learn about multiple myeloma, a disease more than twice as common in people of African descent as in whites. From “Myeloma for Patients Who Are Just Getting Started” to…
Videos
Updates on Efficacy/Safety Results from MonumenTAL-1 (Talquetamab) Presented at ASCO 2022
Dr. Monique C. Minnema Provides Updates on Efficacy/Safety Results from MonumenTAL-1 (Talquetamab) in RRMM patients
Abstract Title:
Efficacy and safety of talquetamab, a G protein-coupled receptor…
Videos
African American SMM Patients Presented at EHA 2022
Dr. Malin Hultcrantz Discusses African American SMM Patients Having Lower Risk of Progression Compared to White SMM Patients at EHA22
Abstract Title:
African American patients with smoldering multiple myeloma may have a lower risk of…
Videos
ctDNA Analysis and Relapse Association in Primary RRMM Patients Presented at ASCO 2022
Dr. Sridurga Mithraprabhu Discusses ctDNA Analysis and Relapse Association in Primary RRMM Patients Receiving Secondary Salvage Therapy
Abstract Title:
Circulating tumor DNA analysis and association with…
Videos
Updated Results on Modakafusp Alfa (TAK-573) Safety and Efficacy; Phase 1/2 Study of RRMM Patients Presented at EHA 2022
Dr. Jonathan L. Kaufman Discusses Safety and Efficacy of Modakafusp Alfa (TAK-573); and Updated Clinical, Pharmacokinetic, and Immunogenicity Results from Phase 1/2 Study in…
Videos
Are treatment options available for patients with smoldering myeloma?
Myeloma expert Dr. Brian G.M. Durie discusses at what point smoldering myeloma patients should consider starting treatment and what options are available.
The BOTTOM LINE: Observation is…
Videos
What Patients and Caregivers Need to Know About Immunotherapy, Bispecific Antibodies, and CAR T-cell Therapy
Speakers
Donna Catamero, ANP-BC, OCN, CCRC (The Mount Sinai Health System, IMF Nurse Leadership)
Tom Martin, MD (University of California San Francisco)…
Videos
Results of the IFM 2014-01 Study Presented at EHA 2022
Dr. Xavier Leleu Explains the Results of Ixazomib, Pomalidomide and Dexamethasone (IxPd) in Relapsed or Refractory Multiple Myeloma Characterized with High-Risk Cytogenetics at EHA 2022
In this Video:
Dr. Xavier Leleu (Centre…
Videos
Subgroup Analyses in RRMM Patients Receiving Real-Life SOC in the LocoMMotion Study at EHA 2022
Dr. Hermann Einsele Discusses the Subgroup Analyses in RRMM Patients Receiving Real-Life SOC in the LocoMMotion Study at the 2022 European Hematology Association (EHA) Congress.
Abstract…
Videos
Phase 1/2 Study: Safety and Efficacy of Belantamab Mafodotin +Rd Presented at EHA 2022
Prof. Evangelos Terpos Discusses Safety and Efficacy of Belantab Mafodotin + Rd in Newly Diagnosed Transplant-Ineligible Myeloma Patients
Abstract Title:
A phase 1/2, dose and schedule evaluation study…
Videos
Updated Study Results of BCMA/CD19 Dual-Targeting CAR-T GC012F Presented at ASCO 2022
Dr. Juan Du Provides Updated Study Results of BCMA/CD19 Dual-Targeting CAR-T GC012F for RRMM Patients
Abstract title:
Updated results of a multicenter first-in-human study of BCMA/CD19 dual-…
Videos
Phase 2 Study IFM 2018-02 (I-Dara) Presented at ASCO 2022
Dr. Xavier Leleu Discusses Phase 2 Study IFM 2018-02 (I-Dara) in Elderly Frail RRMM Patients
Abstract title:
Ixazomib and daratumumab without dexamethasone (I-Dara) in elderly frail relapsed/refractory multiple myeloma (…
Videos
CARTITUDE-2 Cohort A: Updated Clinical Data on Cilta-Cel Presented at ASCO 2022
Prof. Hermann Einsele Provides Updates on Clinical Data of Cilta-Cel in CARTITUDE-2 Cohort A among Progressive Myeloma Patients
Abstract Title:
Biological correlative analyses and updated clinical data of…
Videos
Updated Phase1B Results for Talquetamab in Combination with Daratumumab Presented at EHA 2022
Dr. Dr. Niels W.C.J. van de Donk Discusses Updated Phase1B Results for Talquetamab in Combination with Daratumumab for the Treatment of RRMM Patients
Abstract Title:
Novel Combination…
Videos
Virtual Multiple Myeloma Community Workshop A virtual multiple myeloma workshop addressing the needs specific to communities in the Northeast Region of the United States.The IMF Virtual Regional Community Workshop will include an introduction to myeloma, upfront…
Videos
Updates on Phase 1/2 Trial REGN5458 Presented at EHA 2022
Dr. Joshua Richter Discusses Phase 1/2 Trial REGN5458 (BCMAxCD3 Bispecific Antibody) for RRMM Patients
Abstract Title:
Early, Deep, and Durable Responses, and Low Rates of CRS with REGN5458, a BCMAXCD3 Bispecific…
News Article
Top cancer researchers from across the globe gathered this year for the annual American Society of Clinical Oncology (ASCO) Meeting and European Hematology Association (EHA) Congress. The International Myeloma Foundation (IMF) team is providing these lecture-type video presentations to keep you…
Videos
Phase 3 of the ATLAS Randomized Trial Presented at ASCO 2022
Dr. Dominik Dytfeld Discusses Phase 3 of the ATLAS Trial Comparing Post-ASCT Treatment with KRd Therapy vs Post-ASCT Treatment with R Maintenance
Abstract title:
ATLAS: A phase 3 randomized trial of carfilzomib,…
Videos
Making Sense of Myeloma Treatment
At the IMWG Conference Series, “Making Sense of Treatment,” leading myeloma experts discussed the latest drug therapy news from the June 2022 American Society of Clinical Oncology (ASCO) Annual Conference, IMF IMWG Summit, and the European Hematology Association…